Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.

Gehrig SM, van der Poel C, Hoeflich A, Naim T, Lynch GS, Metzger F.

Growth Horm IGF Res. 2012 Apr;22(2):69-75. doi: 10.1016/j.ghir.2012.02.004. Epub 2012 Mar 15.

PMID:
22424862
2.

The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.

Banks GB, Chamberlain JS.

Curr Top Dev Biol. 2008;84:431-53. doi: 10.1016/S0070-2153(08)00609-1. Review.

PMID:
19186250
3.

Brain function in Duchenne muscular dystrophy.

Anderson JL, Head SI, Rae C, Morley JW.

Brain. 2002 Jan;125(Pt 1):4-13. Review.

PMID:
11834588
4.

Bone tissue and muscle dystrophin deficiency in mdx mice.

Nakagaki WR, Camilli JA.

Joint Bone Spine. 2012 Mar;79(2):129-33. doi: 10.1016/j.jbspin.2011.08.004. Epub 2011 Nov 12. Review. Erratum in: Joint Bone Spine. 2013 Oct;80(5):557-8.

PMID:
22079415
5.

Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.

Kim JH, Kwak HB, Thompson LV, Lawler JM.

J Muscle Res Cell Motil. 2013 Feb;34(1):1-13. doi: 10.1007/s10974-012-9330-9. Epub 2012 Oct 28. Review.

PMID:
23104273
6.

Satellite Cells in Muscular Dystrophy - Lost in Polarity.

Chang NC, Chevalier FP, Rudnicki MA.

Trends Mol Med. 2016 Jun;22(6):479-96. doi: 10.1016/j.molmed.2016.04.002. Epub 2016 May 5. Review.

8.

Functional characteristics of dystrophic skeletal muscle: insights from animal models.

Watchko JF, O'Day TL, Hoffman EP.

J Appl Physiol (1985). 2002 Aug;93(2):407-17. Review.

PMID:
12133845
9.
10.

Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice.

Faulkner JA, Ng R, Davis CS, Li S, Chamberlain JS.

Clin Exp Pharmacol Physiol. 2008 Jul;35(7):725-9. doi: 10.1111/j.1440-1681.2007.04865.x. Epub 2008 Jan 21. Review.

11.

SIRT1: A Novel Target for the Treatment of Muscular Dystrophies.

Kuno A, Horio Y.

Oxid Med Cell Longev. 2016;2016:6714686. doi: 10.1155/2016/6714686. Epub 2016 Mar 17. Review.

12.

Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.

Amthor H, Hoogaars WM.

Curr Gene Ther. 2012 Jun;12(3):245-59. Review.

PMID:
22554312
13.

Myoblast transfer therapy: is there any light at the end of the tunnel?

Mouly V, Aamiri A, Périé S, Mamchaoui K, Barani A, Bigot A, Bouazza B, François V, Furling D, Jacquemin V, Negroni E, Riederer I, Vignaud A, St Guily JL, Butler-Browne GS.

Acta Myol. 2005 Oct;24(2):128-33. Review.

PMID:
16550930
14.

Pharmacologic and genetic therapy for childhood muscular dystrophies.

Escolar DM, Scacheri CG.

Curr Neurol Neurosci Rep. 2001 Mar;1(2):168-74. Review.

PMID:
11898513
15.
16.

Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish.

Kunkel LM, Bachrach E, Bennett RR, Guyon J, Steffen L.

J Hum Genet. 2006;51(5):397-406. Epub 2006 Apr 1. Review.

18.

Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Kornegay JN, Spurney CF, Nghiem PP, Brinkmeyer-Langford CL, Hoffman EP, Nagaraju K.

ILAR J. 2014;55(1):119-49. doi: 10.1093/ilar/ilu011. Review.

19.

Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.

McGreevy JW, Hakim CH, McIntosh MA, Duan D.

Dis Model Mech. 2015 Mar;8(3):195-213. doi: 10.1242/dmm.018424. Review.

20.

Drug Discovery of Therapies for Duchenne Muscular Dystrophy.

Blat Y, Blat S.

J Biomol Screen. 2015 Dec;20(10):1189-203. doi: 10.1177/1087057115586535. Epub 2015 May 14. Review.

PMID:
25975656

Supplemental Content

Support Center